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1EARLY BISPHOSPHONATE TREATMENT IN INFANTS WITH SEVERE
OSTEOGENESIS IMPERFECTA
FRANCO ANTONIAZZI, MD, GIORGIO ZAMBONI, MD, SILVANA LAURIOLA, MD, LUISA DONADI, MD, SILVANO ADAMI, MD, AND
LUCIANO TATÒ, MD
bjective To evaluate prospectively the efficacy of bisphosphonate treatment in infants with severe forms of osteogenesis
mperfecta (OI).
tudy design Of 10 children (6 females) with OI type III, 5 (group A) started treatment (2 mg/kg neridronate administered
ntravenously for 2 consecutive days, every 3 months) just after diagnosis at birth and 5 (group B) after 6 months. Ten
ntreated children, matched for sex, age, and clinical severity of OI, constituted a historical control group (group C). We
easured weight, length, and number of fractures every 3 months and serum and urinary levels of calcium, phosphorus,
reatinine, serum alkaline phosphatase, 25-hydroxyvitamin D, insulin-like growth factor I, parathyroid hormone, and osteo-
alcin, urinary type I collagen N-terminal telopeptide, and lateral radiography of vertebral column every 6 months.
esults Group A had better growth and a lower incidence of fractures than groups B and C in the first 6 months of treatment.
n the second 6 months, both groups A and B had lower fracture rates than group C. After 12 months of therapy, osteocalcin
nd insulin-like growth factor I levels significantly increased only in group A. The urinary Ca/Cr ratio and N-terminal
elopeptide/Cr ratio significantly declined only in treated patients. Vertebral body area and the structure of vertebral bodies
mproved in all treated patients, but especially in group A.
onclusions Cyclical neridronate treatment, started just after diagnosis at birth, had positive effects on growth and fracture
ate. (J Pediatr 2006;149:174-9)
steogenesis imperfecta (OI) is an inherited connective tissue disorder characterized by bone fragility, low bone mass,
and other connective tissue malfunctions.1 Severity varies widely, ranging from intrauterine fractures and perinatal
lethality to very mild forms without fractures. OI type III is characterized by high frequency of fractures from birth,
evere bone deformities, and extreme short stature. Physiotherapy, rehabilitation, and orthopedic surgery are the mainstay of
reatment for these patients.2 Other approaches have been proposed for this type of OI: gene-based or stem cell therapy, which
resently remain in the early stage of research,3 and bisphosphonates.
Bisphosphonates, potent inhibitors of bone resorption with some effects on bone formation,4 demonstrated beneficial
ffects in children affected by severe types of OI.5-10 However, limited data are available on the efficacy of this therapy in children
nder the age of 3 years,11,12 and no controlled studies at present have been conducted in infants from the neonatal period. The
im of this prospective clinical trial was to evaluate the efficacy of bisphosphonate treatment during the first months of life in
nfants affected by severe forms of OI in the hopes of establishing the best age for the start of the therapy and to positively modify
he natural history of the disease.
METHODS
atient Selection
We studied 10 children (6 females) diagnosed as affected by OI type III in the
eonatal period by means of clinical and radiologic evaluation. They were recruited and
andomized consecutively as they were referred to our medical center between 2001 and
003. After diagnosis, at the mean age of 33 days (range 18-44 days, age 0.09  0.01
ears), the patients were divided into 2 groups comparable for sex and clinical severity of
I for an unblinded prospective study.
LP Alkaline phosphatase
GF-I Insulin-like growth factor I
c Osteocalcin
PTH Parathyroid hormone
uNTX Urinary type I collagen N-terminal
telopeptide
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EFive patients (3 females [group A]) started treatment at
mean age of 37 days (range 25-46 days, age 0.10  0.02
ears), just after diagnosis. The other 5 patients (3 females
group B]) were followed up for 6 months and started treat-
ent at a mean age of 220 days (range 203-238 days) (age 0.6
0.04 years). All patients were checked every 3 months until
he age of 18 months (age 1.6  0.05 years).
Ten children, matched for sex, age, and clinical severity
f OI, whose charts were reviewed and collated, constituted
n historical control group (group C). They were first exam-
ned at our institution between 1995 and 2000, before this
tudy was started, therefore they received the same multidis-
iplinary care of the treated patients, including physiotherapy,
ut not bisphosphonate treatment in the first 2 years of life.
nformed consent was obtained from parents, and the study
rotocol was approved and constantly monitored by the local
edical Ethical Committee, under the condition that infants
ere hospitalized during the first treatment cycle.
reatment
Neridronate (6-amino-1-idrossiesilidene-1,1-bisphos-
honate) (Nerixia, Abiogen Pharma, Italy) was administered
t the dose of 2 mg/kg body weight every 3 months. In
articular, the drug was administered by intravenous infusion
t the dose of 1 mg/kg body weight diluted in normal saline
olution to a final concentration of 0.1 mg/mL over a 4-hour
eriod, repeated in the subsequent day. All infusions were
iven into a peripheral vein.
All families received counseling from a nutritionist to
nsure that all patients had a daily intake of vitamin D of at
east 400 IU/d, and of calcium of at least 600 mg/d. All
ubjects underwent specific and individualized physiotherapy.
tudy Design
At the start of the study and every 3 months, weight,
ength, and number of fractures were measured. Routine
lood cell count, blood and urinary levels of calcium, phos-
hate, creatinine, blood alkaline phosphatase (ALP), 25-hy-
roxyvitamin D, parathyroid hormone (PTH), osteocalcin
Oc), and insulin-like growth factor I (IGF-I), urinalysis and
rinary excretion of the bone resorption marker type I colla-
en N-terminal telopeptide (uNTX) were measured at the
eginning and thereafter every 6 months, before infusion of
eridronate. Blood was collected between 10:00 and 12:00
M. Urine specimens were collected between 10 and 12 hours.
ateral X-ray films of vertebral column were obtained at
aseline and every 6 months.
linical Studies
Lengths were obtained with a recumbent length board.
eights were obtained by use of a calibrated scale. Anthro-
ometric measurements were normalized for age and sex and
xpressed in standard deviation score (SDs) calculated as
measured valuemean)/standard deviation with Sempé and
edron tables.13 a
arly Bisphosphonate Treatment In Infants With Severe Osteogenesis ImFracture incidence was assessed by parental recall and
iary and from any available interim radiographs. Fractures
ere confirmed by radiologists blinded to the treatment status
f the subjects. Spine compression fractures were not included
n the analysis, because of the impossibility of accurately
efining vertebral fractures. Pain was evaluated considering
rying during handling and immobilization of a limb.
aboratory Methods
Blood cell count, standard urinalysis, serum and urinary
evels of calcium, phosphate, creatinine and calcium/creati-
ine ratio (uCa/uCr), serum ALP were measured by routine
ethods. Plasma 25-OH D was measured by high-pressure
iquid chromatography (Eureka srl; Chiaravalle, Ancona, It-
ly). The intraassay and interassay coefficients of variations
CVs) were below 5.2% and 7.8%, respectively. The sensitiv-
ty was 5 nmol/L. Serum IGF-I was measured by immuno-
adiometric assay after acid-alcohol extraction (Diagnostic
ystems Laboratories, Webster, TX). The intraassay and in-
erassay CVs were less than 3.4% and 8.2%, respectively. The
ensitivity was 0.1 nmol/L. Serum intact 1-84 PTH levels
ere determined by immunometric chemoluminescence assay
Nichols Institute Diagnostics, San Clemente, CA). The in-
raassay and interassay CVs were less than 6.7% and 9.2%,
espectively. The sensitivity was 0.1 pmol/L. Serum OC was
easured by immunometric chemoluminescence assay (Di-
gnostic Products Corporation, Los Angeles, CA). The in-
raassay and interassay CVs were less than 4.5% and 7.1%,
espectively. The sensitivity was 0.02 nmol/L. Urinary excre-
ion of uNTX was measured by an enzyme immunosorbent
ssay (Osteomark; Ostex, Seattle, WA). Assay values were
xpressed in nanomoles bone collagen equivalents per liter
nmol BCE/L), normalized for urine dilution by urine creat-
nine analysis and reported as nanomoles BCE per mmole
reatinine (uNTX/uCr). The intraassay and interassay CVs
ere less than 9%. The sensitivity was 20 nmol BCE/L.
adiologic Studies
Standard lateral radiographs of the spine were examined
t a magnification of 100% for the measurement of anterior,
osterior, and middle heights of each lumbar vertebral body
L1-L4) to evaluate projected area (cm2, mean L2-L4), shape
bnormalities of lumbar vertebral bodies and to estimate the
ffects of treatment on the spine.14
We were unable to perform in all subjects dual-energy
-ray absorptiometry because the ability to complete measure-
ents was limited at times by the young children being cast
r unable to stay still for the study. Thus, because of ethical
easons (necessity of conscious sedation in such young babies),
echnical difficulties in the evaluation of bone mineral density
easurements and therefore the poor statistical significance of
ur data, we decided not to continue to perform dual-energy
-ray absorptiometry.
Because of the spontaneous decrease in fracture rate
fter birth in patients with type III OI in this age group, the
perfecta 175
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1racture rates before and after treatment were not comparable.
nstead, we compared the fracture rates during the 6-month
eriod in which group A was treated and group B was not,
nd observation for treated patients and control subjects,
onsidering that age and severity were not significantly dif-
erent in the 2 groups.
tatistical Analysis
Descriptive analyses are expressed as mean  standard
eviation (SD). Statistical analyses were performed with un-
aired t test and repeated measures analysis of variance. All
tatistical analyses were performed with a data analysis system
Figure 1. Number of fractures (expressed in no/yr) during different time
intervals: 0-6 months, 6-12 months, 12-18 months. Group A (black bars):
infants treated just after diagnosis; group B (white bars): infants treated
after 6 months of follow-up; group C (gray bars): untreated infants. *P 
.05.
able I. Auxological data (weight and supine length)
nfants affected by severe OI treated with neridronat
Groups T 0
eight (SDs) A 3.2  0.9
B 3.1  0.7
C 3.2  0.6
ength (SDs) A 4.3  1.4
B 4.2  1.3
C 4.5  1.5
rojected Area (cm2) A 1.8 0.5
B 2.0 0.6
C 1.9 0.5
rojected Area (cm2) mean of L2-L4.
roup A: Infants treated just after diagnosis; group B: infants treated after 6 months o
0: age: 0.1  0.02 yrs; first evaluation: group A at the start of treatment;
1: age: 0.6  0.04 yrs; group A after 6 months of treatment: group B at the start of
2: age: 1.1  0.06 yrs; group A after 12 months of treatment: group B after 6 mont
3: age: 1.6  0.05 yrs; group A after 18 months of treatment: group B after 12 mon
 P  .05 vs Group B.
 P  .05 vs Group C.
 P  .01 vs Group C.StatView 4.5; Abacus Concepts, Berkeley, CA) run on an t
76 Antoniazzi et alpple PowerMac Computer (Apple Computer, Cupertino,
alif). Statistical significance was set at P  .05.
RESULTS
linical Data
Infants with severe OI were small-for-age at baseline
Table I); the group as a whole showed both a length-for-age
nd weight-for-age below 2 SD. In untreated patients
group C) there was a significant decrease in mean SD of both
eight and height, confirming the delay in physical develop-
ent typically associated with severe OI.15 In the first 6
onths, patients in group A, treated from the age of 1 month,
rew significantly better in weight and length than those of
roup B and group C (P .05); and patients in group B grew
etter than those in group C after the start of treatment,
eaching a statistically significant difference versus the control
roup at 1.6 years of age (P  .05).
Concerning the fracture rate, the incidence of radiolog-
cally confirmed fractures significantly decreased in group A in
omparison to groups B and C (2.4 vs 6.0 and 6.8 fractures/yr;
 .05) during the first 6 months of treatment. In the second
months, both groups A and B had a significantly lower
racture rate in comparison to group C (2.0 and 2.8 vs 5.4
ractures/yr; P  .05) (Figure 1).
Signs of bone pain, present in all children before ther-
py, tended to disappear in treated infants. The treatment did
ot alter the rate of fracture healing. No fractures sustained on
reatment had clinical or radiographic impairment of healing
s assessed by routine radiologic study. No one child required
ntramedullary rod placement during the study period.
aboratory Data
Baseline Oc and IGF-I levels were significantly lower
tebral projected area and number of fractures in
T 1 T 2 T 3
3.0 0.7*† 2.8 1.0† 2.5  1.2‡
3.6 0.8 3.2 0.9 2.8  1.1†
3.7 1.0 3.8 1.1 3.7  1.3
3.8 1.2*† 3.5 1.3‡ 3.4  1.1‡
4.5 1.4 3.9 1.5 3.7  1.4†
4.8 1.4 4.9 1.5 5.1  1.7
4.0 0.8*† 5.1 1.0† 5.8 1.1†
3.2 0.7 4.5 0.9 5.2  1.2
3.1 0.8 3.8 0.9 4.3  1.0
w-up; group C: untreated infants.
ent;
eatment;
treatment., ver
e
f follo
treatm
hs of tr
ths ofhan our normal levels for age, whereas calcium, phosphate,
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ELP, 25-OH D and PTH were in the normal range for age
Table II). Urinary uCa/ucCr ratio and uNTX/uCr ratio were
ignificantly higher than normal values for age.
During neridronate therapy there were no significant
hanges in serum calcium, phosphate, and 25-OH D, and a
light rise in ALP and PTH levels. Osteocalcin levels in-
reased in group A from 2.5  1.0 at the beginning to 5.4 
.1 nmol/L after 12 months (P  .05 vs group C), but they
emained in the lower range of normal values. IGF-I levels
ncreased in groups A and B after the start of treatment, but
he increment was statistically significant only in group A (P
.05 vs group C). Urine uCa/uCr ratio and uNTX/uCr ratio
howed a significant decline over time, and uNTX/uCr ratio
evels were significantly lower in treated compared with un-
able II. Biochemical data in infants affected by seve
Groups T 0
lood
Calcium (mmol/L) A 2.4 0.1 2.5
B 2.5 0.2 2.4
C 2.4  0.2 2.3
Phosphate (mmol/L) A 2.1 0.2 2.2
B 2.2 0.1 2.1
C 2.0  0.2 2.1
ALP (IU/L) A 318 58 366
B 332 53 352
C 320 47 348
25-hydroxyvitamin D (nmol/L) A 39 10 44
B 37  11 48
C 40  11 46
Intact PTH (pmol/L) A 2.6 1.1 3.0
B 2.9 1.2 3.1
C 3.0  1.3 3.1
Osteocalcin (nmol/L) A 2.5 1.0 4.1
B 2.3 1.1 3.8
C 2.6  1.0 3.6
IGF-I (nmol/L) A 2.9 0.9 4.8
B 2.6 0.8 3.2
C 2.7  0.7 3.1
rine
uCa/uCr (mol/mmol) A 800 220 635
B 750 215 800
C 770 232 790
uNTX/uCr (nmol BCE/mmol) A 1900 350 1350
B 1880 310 1950
C 1850  335 1910
roup A: infants treated just after diagnosis; group B: infants treated after 6 months o
0: age: 0.1  0.02 yrs; first evaluation: group A at the start of treatment;
1: age: 0.6  0.04 yrs; group A after 6 months of treatment: group B at the start of
2: age: 1.1  0.06 yrs; group A after 12 months of treatment: group B after 6 mont
3: age: 1.6  0.05 yrs; group A after 18 months of treatment: group B after 12 mon
Normal values for age in our laboratory.
 P  .05 vs Group B.
 P  .05 vs Group C.reated patients (P  .05 vs group C). c
arly Bisphosphonate Treatment In Infants With Severe Osteogenesis Imadiologic Studies
Before treatment, lateral X-ray films of vertebral col-
mn showed severe vertebral body deformities, such as flat-
ened or wedged vertebrae, in all patients. An increase in
ertebral size on the lateral view of the spine and in projected
ertebral body area was found in all treated patients, but the
ifference became statistically significant only in group A with
espect to the untreated group (P  .05 vs group C), sug-
esting that more new bone formed (Table I).
Figure 2 shows lateral X-ray films of the column in the
ame infant treated with neridronate from the age of 1 month,
t the beginning and after 6 and 12 months of treatment. The
rogressive improvement in the structure of vertebral bodies
nd a correction of deformities is evident. Other radiologic
I treated with neridronate
T 2 T 3 Normal values for age*
.2 2.5 0.2 2.4 0.1 2.1–2.65
.1 2.3 0.1 2.3 0.2
.2 2.4 0.1 2.3 0.2
.3 2.2 0.2 2.3 0.3 1.6–2.6
.2 2.2 0.3 2.2 0.2
.2 2.2 0.2 2.1 0.3
6 418 85 406 89 200–600
7 396 88 397 78
4 368 75 355 82
2 51  13 52  12 24–120
3 54  14 49  12
4 48  13 50  13
.3 3.2 1.1 3.2 1.0 1.1–5.8
.2 3.3 1.4 3.3 1.3
.3 3.2 1.3 3.1 1.2
.3 5.4 1.1b 5.2  1.8 4.2–10.3
.2 4.9 1.3 6.1 1.9
.1 4.0 1.2 4.2 1.4
.4ab 5.2  1.8b 5.4  1.6b 3.7–20.4
.5 4.9 2.1 5.1 2.2
.3 3.7 1.6 3.8 1.5
35 580 216 650 148 1 year 90–2,200; 1–2 yrs
70–1,500
55 600 264 640 206
80 730 295 710 212
34ab 1200 388b 1170 337 1 year 1,400–2,200; 1–2
yrs 800–1,500
10 1380 355b 1295 328
90 1870 340 1650 440
w-up; group C: untreated infants.
ent;
eatment;
treatment.re O
T 1
 0
 0
 0
 0
 0
 0
 4
 5
 5
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 2
 2
 2
 3
 4
 3
f follo
treatm
hs of tr
ths ofhanges included decreased deformities of long bones in all
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1atients. Radiographs showed discrete dense parametaphyseal
ines corresponding to the time of each treatment cycle in all
atients, confirming that linear growth continued.
ide Effects
Considering the possible adverse side effects of treat-
ent, we only noted the well-known acute phase reaction
fter the first infusion cycle in 9 patients,16 with short-term
ever up to 38.5° C responsive to acetaminophen. During
reatment, none of our patients showed urinary protein ex-
retion, white blood cell count reduction, or respiratory dis-
ress syndrome.17 No infant missed a scheduled infusion
ecause of difficulty with the protocol.
DISCUSSION
Bisphosphonates represent a class of drugs that are
otent inhibitors of bone resorption4 and are widely used to
reat children5-10 and adults18 with osteogenesis imperfecta.
ittle experience is available on the effect of these drugs in the
oungest infants11,12 and the optimal age to start bisphospho-
ate treatment is unknown. We compared 2 groups, one that
tarted treatment just after diagnosis at birth, and the other 6
onths later. We judged it unethical to perform placebo
nfusions at this age and incorporate an untreated control
roup, because some data suggest that bisphosphonate ther-
py is beneficial and that there is no other established phar-
acologic treatment. Therefore we chose an open study de-
ign and compared the results of the 2 treated groups with
hose of a historical control group of patients previously seen
n our unit. This is, to our knowledge, the first controlled
tudy conducted of infants with OI from the neonatal period.
igure 2. Lateral X-ray films of column in infant treated with
eridronate from age 1 month; (a) at beginning, (b) after 6 months, and
c) after 12 months of treatment. It is evident progressive improvement of
ertebral bodies.In our patients with OI, baseline height and weight m
78 Antoniazzi et alere low for age. Neridronate did not have a detrimental
ffect on growth; in fact, we found an increase in SD score of
rowth parameters in all treated children in comparison to the
ecrease in SD score in the control group. These results
onfirm previous studies that reported a significant height
ain in moderately to severely affected patients with OI.19
In our patients, the response to treatment appeared
ore pronounced than in older children. This better gain is
robably due to the younger age of patients; in fact, during
rst and second year height velocity is very high and also a
mall percentage in height velocity gain results in a great
ositive difference.
At the age of our patients, it is difficult to interpret the
ignificance of change in fracture rate. Because many infants
ustain fractures either prenatally or perinatally and fracture
ate may relate to the degree of birth trauma, we excluded
ractures present at birth. Moreover, some fractures may not
e diagnosed radiographically or clinically or may be influ-
nced by external factors (mode of handling, mobility), and
racture rates may also decrease spontaneously with increasing
ge.15 For these reasons, a change in fracture rates in very
oung children as a result of intravenous bisphosphonate is
ot easy to demonstrate. Thus we compared treated with
ntreated patients, even though patients from group C did
ot use the same protocol for nonpharmacologic therapy. A
ecrease in fracture rate has been described previously in older
hildren with severe OI treated with long-term intravenous
amidronate,7,11,12 neridronate,10 or olpadronate.9,20 In our
xperience, though, during the study period, the treated pa-
ients had increased mobility and therefore presented a higher
isk of injury and became more susceptible to fractures, we
oted that intravenous neridronate significantly reduced frac-
ure rates, suggesting a direct effect of the therapy.
Our results confirm that infants with severe OI have a
igh bone turnover rate before therapy, as previously report-
d.8,12 This may be a primary or secondary effect of the
isease, related to immobilization from fractures as suggested
y the hypercalcemia and mild hypercalciuria.21
With treatment, however, markers of bone turnover
ecreased as a direct consequence of intravenous bisphospho-
ate therapy.12 We measured bone metabolic markers only
efore infusion of bisphosphonate, and thus we cannot doc-
ment their variations after the drug administration, with the
ostulated drop in serum calcium with transitory increase in
TH levels and the possible effect of these bursts of PTH
ecretion on the reported increase in BMD in older patients.22
n the first months of treatment, we found a significant
ncrease in IGF-I levels in patients of group A, correlated to
igher growth velocity and probably related also to the in-
rease in osteocalcin levels. We cannot say if this is due to the
ncrease of physical activity, which is not easy to quantify at
his age, or to a direct variation of catabolic pattern in a more
nabolic one, as just elegantly postulated.23 The mechanisms
f action of bisphosphonates, in fact, seem to involve both
nhibition of osteoclastic resorption and stimulation of PTH-
ediated anabolic effects on osteoblastic processes. The evi-
The Journal of Pediatrics • August 2006
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Eence of a shift from catabolic to anabolic pattern of bone may
e confirmed also by the increase in vertebral size and appar-
nt reshaping of both vertebrae and long bones in treated
atients. In this bone anabolic process, the amount of physical
xercise is also probably involved, because of the increase of
he maximal isometric grip force reported after bisphospho-
ate treatment in children with severe forms of OI.24
Although there is no consensus on optimal dosing or
ge of start of treatment, our data show that treatment with
ntravenous neridronate from ages as young as 1 month is an
ffective treatment for reducing fractures. Although bisphos-
honate treatment is a symptomatic not curative treatment
hat does not alter the genetic defect underlying OI, it is an
djunct to physiotherapy, rehabilitation, and orthopedic care
hat must be continued carefully. The optimal treatment
chedule and the length and the long-term outcomes of
isphosphonate therapy are unclear at present25; however,
yclical neridronate treatment, started as soon as possible, just
fter diagnosis at birth, seems to have the best positive effect
n growth, fracture rate, and skeletal improvement at an age
ery important for psychological and motor development.26
e thank the Italian Association of patients with OI (AsItOI),
arents of children who took part in the study and Abiogen
harma (Pisa, Italy) for providing the study medication.
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